Atypical hemolytic–uremic syndrome is a genetic, life-threatening, chronic disease of complement-mediated thrombotic microangiopathy. Plasma exchange or infusion may transiently maintain normal levels ...
The market for complement inhibitors is expected to grow significantly in the coming years. Since the launch of SOLIRIS and ULTOMIRIS, the complement inhibitor market has seen a lot of traction, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results